SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Toronto Stock Exchange |
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On May 24, 2022, the Board of Directors of Bausch Health Companies Inc. (“Company”) appointed John S. Barresi, 49, as the Company’s Senior Vice President, Controller and Chief Accounting Officer. Prior to his appointment, Mr. Barresi served as the Senior Vice President of Finance and Chief Accounting Officer of Bed Bath & Beyond, Inc. (“BBBY”). Prior to joining BBBY, Mr. Barresi served in various leadership roles at Tiffany & Co., including Vice President, Global Business Transformation from February 2017 through June 2021, Vice President, Controller from June 2013 through June 2017, and Vice President, Internal Audit and Financial Controls from April 2009 through June 2013. Earlier in his career, Mr. Barresi worked in public accounting with PricewaterhouseCoopers LLP.
The company has entered into an offer letter (“Offer Letter”) with Mr. Barresi. Under the terms of the Offer Letter, Mr. Barresi will receive an annual base salary of $425,000 and will be eligible to receive an annual cash bonus with a target of 50% of his base salary which will be prorated based on his start date. In consideration for the compensation Mr. Barresi will forfeit by leaving his current employer, Mr. Barresi will also receive a one-time sign-on cash bonus of $100,000, and a one-time sign-on equity grant with an aggregate grant date fair value of $150,000 to be delivered 100% in the form of restricted stock units granted under the Bausch Health Companies Inc. 2014 Omnibus Incentive Plan (as Amended and Restated, Effective as of April 28, 2020 (or any applicable successor plan thereto)). If Mr. Barresi voluntarily resigns at any time within the first two years of his employment, he will be required to repay the after-tax amount of the sign-on bonus to the company. Under the Company’s US Severance Pay Plan, if the Company terminates Mr. Barresi’s employment without cause, he will receive, subject to continued compliance with post-termination obligations and executing and not revoking a release of claims, an amount equal to his base salary, paid in normal payroll installments, for a period of 52 weeks following the date of termination.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BAUSCH HEALTH COMPANIES INC. | ||
| By: | /s/ Seana Carson | |
| Name: | Seana Carson | |
| Title: | Executive Vice President, General Counsel | |
Date: May 31, 2022
Document and Entity Information |
May 24, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Document Period End Date | May 24, 2022 |
| Entity Registrant Name | Bausch Health Companies Inc. |
| Entity Incorporation, State or Country Code | A1 |
| Entity File Number | 001-14956 |
| Entity Tax Identification Number | 98-0448205 |
| Entity Address, Address Line One | 2150 St. Elzéar Blvd. West |
| Entity Address, City or Town | Laval |
| Entity Address, State or Province | QC |
| Entity Address, Country | CA |
| Entity Address, Postal Zip Code | H7L 4A8 |
| City Area Code | 514 |
| Local Phone Number | 744-6792 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Shares, No Par Value |
| Trading Symbol | BHC |
| Security Exchange Name | NYSE |
| Entity Emerging Growth Company | false |
| Entity Central Index Key | 0000885590 |
| Amendment Flag | false |